Pluristem Therapeutics Company Profile (NASDAQ:PSTI)

About Pluristem Therapeutics

Pluristem Therapeutics logoPluristem Therapeutics Inc. (Pluristem) is a bio-therapeutics company developing off-the-shelf allogeneic cell therapy products for the treatment of multiple ischemic and inflammatory conditions. The Company focuses on cardiovascular, orthopedic, pulmonary, hematological and women's health diseases. The Company is focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's placenta expanded (PLX) cells are intended to function as a platform that releases a number of therapeutic proteins in response to various local and systemic inflammatory and ischemic signals that are generated by the patient's own body. PLX cells are grown using its three-dimensional (3D), micro environment technology, which produces a product that requires no tissue matching prior to administration. Its PLX products are in clinical-stage development for multiple indications.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PSTI
  • CUSIP:
Key Metrics:
  • Previous Close: $1.55
  • 50 Day Moving Average: $1.6549
  • 200 Day Moving Average: $1.5691
  • 52-Week Range: $0.71 - $1.86
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.15
  • P/E Growth: 0.0000
  • Market Cap: $127.53M
  • Outstanding Shares: 80,723,000
  • Beta: 0.59
Profitability:
  • Net Margins: -736.46%
  • Return on Equity: -50.84%
  • Return on Assets: -43.81%
Debt:
  • Current Ratio: 6.17%
  • Quick Ratio: 6.17%
Additional Links:
Companies Related to Pluristem Therapeutics:

Analyst Ratings

Consensus Ratings for Pluristem Therapeutics (NASDAQ:PSTI) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.17 (160.42% upside)
Analysts' Ratings History for Pluristem Therapeutics (NASDAQ:PSTI)
Show:
DateFirmActionRatingPrice TargetDetails
9/12/2016Maxim GroupReiterated RatingBuy$3.00View Rating Details
8/4/2016HC WainwrightReiterated RatingBuy$3.50View Rating Details
7/11/2016FBR & CoReiterated RatingBuyView Rating Details
8/14/2015MLV & Co.Reiterated RatingBuy$6.00View Rating Details
2/3/2015Needham & Company LLCLower Price TargetBuy$5.00 -> $4.00View Rating Details
(Data available from 9/30/2014 forward)

Earnings

Earnings History for Pluristem Therapeutics (NASDAQ:PSTI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
11/24/2014($0.13)($0.09)ViewN/AView Earnings Details
10/6/2014($0.13)($0.09)ViewN/AView Earnings Details
9/11/2014($0.15)($0.09)ViewN/AView Earnings Details
5/22/2014($0.14)($0.14)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Pluristem Therapeutics (NASDAQ:PSTI)
Current Year EPS Consensus Estimate: $-0.30 EPS
Next Year EPS Consensus Estimate: $-0.26 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.10)($0.10)($0.10)
Q2 20161($0.10)($0.10)($0.10)
Q4 20161($0.09)($0.09)($0.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Pluristem Therapeutics (NASDAQ:PSTI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Pluristem Therapeutics (NASDAQ:PSTI)
Insider Ownership Percentage: 8.17%
Institutional Ownership Percentage: 3.72%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/22/2016Zami AbermanCEOBuy5,000$1.33$6,650.00View SEC Filing  
2/18/2016Yaky YanayCFOBuy5,000$1.20$6,000.00View SEC Filing  
2/16/2016Yaky YanayCFOBuy15,000$0.95$14,250.00View SEC Filing  
2/15/2016Doron ShorrerDirectorBuy12,346$0.81$10,000.26View SEC Filing  
2/12/2016Yaky YanayCFOBuy5,000$0.83$4,150.00View SEC Filing  
2/11/2016Israel Ben-YoramDirectorBuy10,000$0.79$7,900.00View SEC Filing  
2/11/2016Zami AbermanCEOBuy31,000$0.80$24,800.00View SEC Filing  
11/16/2015Yaky YanayCFOBuy10,000$1.52$15,200.00View SEC Filing  
11/16/2015Zami AbermanCEOBuy9,900$1.49$14,751.00View SEC Filing  
9/21/2015Israel Ben-YoramDirectorSell30,000$2.10$63,000.00View SEC Filing  
9/21/2015Yaky YanayCFOBuy10,000$2.11$21,100.00View SEC Filing  
9/21/2015Zami AbermanCEOBuy25,500$2.11$53,805.00View SEC Filing  
9/16/2015Yaky YanayCFOBuy10,000$2.12$21,200.00View SEC Filing  
9/15/2015Zami AbermanCEOBuy25,000$2.11$52,750.00View SEC Filing  
11/11/2014Yaky YanayCOOBuy11,000$2.62$28,820.00View SEC Filing  
11/11/2014Zami AbermanCEOBuy13,000$2.64$34,320.00View SEC Filing  
9/22/2014Yaky YanayCOOBuy11,000$2.95$32,450.00View SEC Filing  
9/22/2014Zami AbermanCEOBuy5,000$2.92$14,600.00View SEC Filing  
9/21/2014Zami AbermanCEOBuy5,000$2.96$14,800.00View SEC Filing  
9/17/2014Israel Ben-YoramDirectorBuy5,000$2.82$14,100.00View SEC Filing  
9/16/2014Boaz Gur-LavieCFOBuy3,478$2.84$9,877.52View SEC Filing  
9/16/2014Yaky YanayCOOBuy10,000$2.85$28,500.00View SEC Filing  
9/16/2014Zami AbermanCEOBuy15,000$2.80$42,000.00View SEC Filing  
6/18/2014Mark GermainDirectorSell43,215$3.12$134,830.80View SEC Filing  
1/17/2014Israel Ben-YoramDirectorSell35,625$4.51$160,668.75View SEC Filing  
1/13/2014Israel Ben-YoramDirectorSell26,453$4.29$113,483.37View SEC Filing  
1/13/2014Yaky YanayCFOSell69,850$4.29$299,656.50View SEC Filing  
1/9/2014Yaky YanayCFOSell30,150$4.25$128,137.50View SEC Filing  
1/8/2014Israel Ben-YoramDirectorSell44,797$4.12$184,563.64View SEC Filing  
11/11/2013Nachum RosmanDirectorSell67,244$3.27$219,887.88View SEC Filing  
9/12/2013Israel Ben-YoramDirectorSell52,000$3.07$159,640.00View SEC Filing  
5/20/2013Israel Ben-YoramDirectorSell45,429$3.03$137,649.87View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Pluristem Therapeutics (NASDAQ:PSTI)
DateHeadline
News IconWhat are Research Firms Saying About Pluristem Therapeutics, Inc. (NASDAQ:PSTI)? - Frisco Fastball (NASDAQ:PSTI)
friscofastball.com - September 30 at 3:25 PM
News IconCatching the Wonder of Investors: Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Duncan Research (NASDAQ:PSTI)
www.duncanindependent.com - September 30 at 3:25 PM
News IconInterested Penny Stock Investors Keen on Shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Duncan Research (NASDAQ:PSTI)
www.duncanindependent.com - September 29 at 12:02 PM
News IconUpgrades And Downgrades For Pluristem Therapeutics, Inc. (PSTI) - NewsDen (NASDAQ:PSTI)
newsden.net - September 29 at 12:02 PM
capitalcube.com logoPluristem Therapeutics, Inc. is trading above its 50 day moving average : PSTI-US : September 28, 2016 (NASDAQ:PSTI)
www.capitalcube.com - September 28 at 12:05 PM
News IconPenny Stock Investors are Growing Curious About Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Duncan Research (NASDAQ:PSTI)
www.duncanindependent.com - September 27 at 6:46 PM
News IconKeen Investors Find News on Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Duncan Research (NASDAQ:PSTI)
www.duncanindependent.com - September 23 at 6:23 PM
News IconUnder the Microscope, Zeroing in at Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Duncan Research (NASDAQ:PSTI)
www.duncanindependent.com - September 22 at 11:42 AM
finance.yahoo.com logoPluristem Therapeutics, Inc. - "Biotech Nation" (NASDAQ:PSTI)
finance.yahoo.com - September 22 at 11:42 AM
News IconPenny Stock Investors Keen on Shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Duncan Research (NASDAQ:PSTI)
www.duncanindependent.com - September 21 at 6:29 PM
investornewswire.com logoShares Of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Expected To Hit $6 - Investor Newswire (NASDAQ:PSTI)
www.investornewswire.com - September 20 at 12:10 PM
News IconPenny Stock Investors Take an Interest in Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Duncan Research (NASDAQ:PSTI)
www.duncanindependent.com - September 20 at 12:10 PM
insidermonkey.com logoPluristem Therapeutics Inc. (PSTI) Gears Up For Critical Blood Stem Cell Trial - Insider Monkey (blog) (NASDAQ:PSTI)
www.insidermonkey.com - September 19 at 6:50 PM
News IconPluristem Therapeutics Inc. (PSTI) Gears Up For Critical Blood Stem Cell Trial (NASDAQ:PSTI)
feedproxy.google.com - September 19 at 11:58 AM
News IconKeen Investors Seek Information on Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Duncan Research (NASDAQ:PSTI)
www.duncanindependent.com - September 17 at 11:19 AM
News IconStock Update, a Closer Look at Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Duncan Research (NASDAQ:PSTI)
www.duncanindependent.com - September 16 at 10:27 AM
marketexclusive.com logoPluristem Therapeutics Inc. (NASDAQ:PSTI) Gears Up For Critical Blood Stem Cell Trial - Market Exclusive (NASDAQ:PSTI)
marketexclusive.com - September 16 at 10:27 AM
4-traders.com logoPluristem Therapeutics : Advances Towards U.S. Clinical Trial in PLX-R18 and Announces Principal Investigator (NASDAQ:PSTI)
www.4-traders.com - September 15 at 6:57 PM
marketexclusive.com logoPluristem Therapeutics Inc. (NASDAQ:PSTI) Gears Up For Critical Blood Stem Cell Trial (NASDAQ:PSTI)
marketexclusive.com - September 15 at 10:27 AM
News IconPluristem Advances Towards U.S. Clinical Trial in PLX-R18 and Announces Principal Investigator - EconoTimes (NASDAQ:PSTI)
www.econotimes.com - September 14 at 7:01 PM
News IconKeen Investors Narrowing Their Focus on Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Duncan Research (NASDAQ:PSTI)
www.duncanindependent.com - September 14 at 7:01 PM
publicnow.com logoPluristem Advances Towards U.S. Clinical Trial in PLX-R18 and Announces Principal Investigator (NASDAQ:PSTI)
www.publicnow.com - September 14 at 11:14 AM
capitalcube.com logoPluristem Therapeutics, Inc. :PSTI-US: Earnings Analysis: 2016 By the Numbers : September 13, 2016 (NASDAQ:PSTI)
www.capitalcube.com - September 13 at 11:46 AM
globenewswire.com logoPluristem Provides Fiscal Year 2016 Corporate and Financial Highlights - GlobeNewswire (press release) (NASDAQ:PSTI)
globenewswire.com - September 12 at 6:33 PM
News IconGetting a Closer Look at Shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Duncan Research (NASDAQ:PSTI)
www.duncanindependent.com - September 12 at 6:33 PM
publicnow.com logoPluristem Provides Fiscal Year 2016 Corporate and Financial Highlights (NASDAQ:PSTI)
www.publicnow.com - September 12 at 11:32 AM
globenewswire.com logoPluristem to Conduct Symposium on PLX-PAD Potential for the Treatment of Peripheral Artery Disease at a ... - GlobeNewswire (press release) (NASDAQ:PSTI)
globenewswire.com - September 9 at 6:32 PM
News IconFocusing the Spotlight on Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Duncan Research (NASDAQ:PSTI)
www.duncanindependent.com - September 9 at 6:32 PM
News IconMaking News: Targeting shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Duncan Research (NASDAQ:PSTI)
www.duncanindependent.com - September 9 at 6:32 PM
News IconPlacing Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Shares Under the Microscope - National Daily Press (NASDAQ:PSTI)
www.nationaldailypress.com - September 9 at 6:32 PM
News IconNarrowing the Lens on Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Duncan Research (NASDAQ:PSTI)
www.duncanindependent.com - September 8 at 10:45 AM
News IconConsensus Take: Pluristem Therapeutics, Inc. (NASDAQ:PSTI ... - Frisco Fastball (NASDAQ:PSTI)
friscofastball.com - September 8 at 10:45 AM
finance.yahoo.com logoPluristem to Conduct Symposium on PLX-PAD Potential for the Treatment of Peripheral Artery Disease at a Multinational Conference on Vascular Medicine (NASDAQ:PSTI)
finance.yahoo.com - September 8 at 10:45 AM
biz.yahoo.com logoPLURISTEM THERAPEUTICS INC Files SEC form 10-K, Annual Report (NASDAQ:PSTI)
biz.yahoo.com - September 7 at 7:02 PM
News IconOTC Investors Supremely Interested in Shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Duncan Research (NASDAQ:PSTI)
www.duncanindependent.com - September 6 at 6:59 PM
News IconUnder the Magnifying Glass: A Closer Look at Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Duncan Research (NASDAQ:PSTI)
www.duncanindependent.com - September 1 at 6:52 PM
investornewswire.com logoCan Shares Of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Get To $6? - Investor Newswire (NASDAQ:PSTI)
www.investornewswire.com - August 30 at 6:50 PM
News IconZeroing Our Focus on Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Duncan Research (NASDAQ:PSTI)
www.duncanindependent.com - August 30 at 6:50 PM
4-traders.com logoPluristem Therapeutics : PSTI) Secures $8 Million EU Grant for Critical Limb Ischemia Study (NASDAQ:PSTI)
www.4-traders.com - August 25 at 7:06 PM
News IconPenny Stock Under the Microscope: Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Duncan Research (NASDAQ:PSTI)
www.duncanindependent.com - August 25 at 12:03 PM
News IconLooking Closer at Stocks of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Duncan Research (NASDAQ:PSTI)
www.duncanindependent.com - August 24 at 6:43 PM
News IconPluristem advances its u. s. fda trial in hematologic indication – nasdaq. com moto x data recovery (NASDAQ:PSTI)
handyrecovery.in - August 20 at 6:37 PM
News IconStock Moving Up in Trade: Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Post News (NASDAQ:PSTI)
www.kentuckypostnews.com - August 18 at 7:08 PM
News IconA Closer Look at Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Duncan Research (NASDAQ:PSTI)
www.duncanindependent.com - August 17 at 9:57 AM
News IconSmall Cap Update on: Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Duncan Research (NASDAQ:PSTI)
www.duncanindependent.com - August 15 at 7:20 PM
investornewswire.com logoWill Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Hit $6 Price Target? - Investor Newswire (NASDAQ:PSTI)
www.investornewswire.com - August 15 at 7:20 PM
insidermonkey.com logoWill Pluristem Therapeutics Inc. (PSTI) Succeed in CLI Where Sanofi SA (ADR) (SNY) Failed? - Insider Monkey (blog) (NASDAQ:PSTI)
www.insidermonkey.com - August 12 at 10:08 AM
streetinsider.com logoPluristem Therapeutics (PSTI) Receives $8M Grant for Phase III Critical Limb Ischemia Study - StreetInsider.com (NASDAQ:PSTI)
www.streetinsider.com - August 11 at 7:28 PM
investors.com logoPluristem receives US$8mln EU grant for limb threat trial (NASDAQ:PSTI)
www.proactiveinvestors.com - August 9 at 7:13 PM
publicnow.com logoPluristem’s Phase III Critical Limb Ischemia Study Wins $8 Million Grant from Europe’s Horizon 2020 Program (NASDAQ:PSTI)
www.publicnow.com - August 9 at 10:09 AM

Social

Pluristem Therapeutics (NASDAQ:PSTI) Chart for Friday, September, 30, 2016


Last Updated on 9/30/2016 by MarketBeat.com Staff